期刊文献+

瑞舒伐他汀对冠心病患者血清Vaspin、ROCK活性及FMD的影响及其临床意义 被引量:4

Effect of Rosuvastatin on serum Vaspin, ROCK activity and FMD in patients with CHD and its clinical significance
下载PDF
导出
摘要 目的 探讨瑞舒伐他汀对冠心病(CHD)患者血清腹腔脂肪型丝氨酸蛋白酶抑制剂(Vaspin)水平、Rho激酶(ROCK)活性、肱动脉血流介导的舒张功能(FMD)的影响及其临床意义.方法 选取2015年7月至2016年7月在我院诊治的120例CHD患者,采用前瞻性随机研究方法分为瑞舒伐他汀组和阿托伐他汀组各60例.两组患者均采用一致的基础治疗,对比两组治疗8周后的血清Vaspin、ROCK活性、FMD等指标.结果 治疗后,瑞舒伐他汀组与阿托伐他汀组比较,TG[(1.20±0.35)mmol/L比(1.28±0.37)mmol/L]、TC[(4.41±0.85)mmol/L比(4.60±0.76)mmol/L]、LDL-C[(1.56±0.45)mmol/L比(1.71±0.48)mmol/L]、HDL-C[(1.29±0.22)mmol/L比(1.22±0.27)mmol/L]未见统计学差异(P〉0.05).治疗后,瑞舒伐他汀组的ROCK活性低于阿托伐他汀组[(40.8±6.3)%比(45.2±7.0)%](P〈0.05),FMD[(7.86±1.59)%比(6.82±1.63)%]、 血清Vaspin[(1.74±0.32)ng/ml比(1.48±0.39)ng/ml]高于阿托伐他汀组(P〈0.05).瑞舒伐他汀组的血清IL-6[(200.7±32.5)pg/ml比(228.1±34.0)pg/ml]、IL-10[(20.9±2.4)ng/ml比(22.6±2.8)ng/ml]、TNF-α[(2.21±0.39)ng/ml比(2.65±0.44)ng/ml]水平低于阿托伐他汀组(P〈0.05).结论 瑞舒伐他汀能抑制CHD患者ROCK活性,提高FMD及Vaspin水平,降低血清炎性因子水平. Objective To study the effect of Rosuvastatin on coronary heart disease (CHD) patients on serum vaspin (Vaspin), Rho kinase (ROCK) activity, brachial artery flow mediated dilation (FMD) effect. Methods From July 2015 to July 2016 in 120 patients with CHD in our hospital, a prospective randomized study method divided into Rosuvastatin group and Atorvastatin group with 60 cases in each group, two groups of patients were treated with the same basic treatment, comparing the two groups after 8 weeks of treatment, serum Vaspin, ROCK activity, FMD index. Results After treatment, Rosuvastatin group TG (1.20 ±0.35)mmol/L, TC (4.41 ± 0.85)mmol/L, LDL-C (1.56±0.45)mmol/L, HDL-C (1.29±0.22)mmol/L, Atorvastatin group TG (1.28±0.37) mmol/L, TC(4.60±0.76)mmol/L, LDL-C(1.71±0.48)mmol/L, HDL-C(1.22±0.27)mmol/L, comparison the dif-ference was not statistically significant(P〉0.05). After treatment, the ROCK activity(40.8±6.3)% in Rosuvastatin group was lower than that in Atorvastatin group(45.2±7.0)%(P〈0.05), the FMD(7.86±1.59)% and serum Vaspin (1.74±0.32)ng/ml in Rosuvastatin group were higher than that of Atorvastatin group FMD (6.82±1.63)%, serum Vaspin(1.48±0.39)ng/ml(P〈0.05), the serum IL-6 of Rosuvastatin group(200.7±32.5)pg/ml, IL-10(20.9± 2.4)ng/ml, TNF-α(2.21±0.39) was lower than Atorvastatin group IL-6(228.1±34.0)pg/ml, IL-10(22.6±2.8)ng/ml, TNF-α(2.65±0.44)ng/ml(P〈0.05). Conclusion Rosuvastatin can inhibit the activity of ROCK, increase the lev-el of FMD and Vaspin, and decrease the level of serum inflammatory factors in patients with CHD.
作者 刘琨 赵云峰 李公豪 LIU Kun ZHAO Yun-feng LI Gong-hao.(Department of Cardiology, Lianyungang First People's Hospital, Lianyungang 222000, Chin)
出处 《中国心血管病研究》 CAS 2017年第7期655-659,共5页 Chinese Journal of Cardiovascular Research
关键词 冠状动脉疾病 丝氨酸蛋白酶抑制剂 RHO激酶 舒张功能 Coronary heart disease Serine proteinase inhibitor Rho kinase Diastolic function
  • 引文网络
  • 相关文献

参考文献12

二级参考文献210

共引文献607

同被引文献42

引证文献4

二级引证文献41

;
使用帮助 返回顶部